High cholesterol secondary prevention: Difference between revisions
Kashish Goel (talk | contribs) No edit summary |
Kashish Goel (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
__NOTOC__ | __NOTOC__ | ||
==Overview== | ==Overview== | ||
Patients with [[coronary heart disease]] or newly diagnosed [[acute coronary syndrome]] are at a high risk of recurrent coronary events. In addition to modification of lifestyle factors, LDL lowering has been shown to reduce recurrent events, cardiovascular deaths and all-cause mortality in these patients. According to the [[NCEP ATP III guidelines]], LDL cholesterol of < 100 mg/dL is the goal in patients with CHD and CHD risk equivalents. The NCEP recommendations are mentioned here, in addition to recent evidence. | Patients with [[coronary heart disease]] or newly diagnosed [[acute coronary syndrome]] are at a high risk of recurrent coronary events. In addition to modification of lifestyle factors, LDL lowering has been shown to reduce recurrent events, cardiovascular deaths and all-cause mortality in these patients. According to the [[NCEP ATP III guidelines]], LDL cholesterol of < 100 mg/dL is the goal in patients with CHD and CHD risk equivalents. The NCEP recommendations are mentioned here, in addition to recent evidence. | ||
==Therapy goals== | ==Therapy goals== | ||
NCEP ATP III guidelines recommended a LDL goal < 100 mg/dL for CHD or CHD risk equivalents, however drug therapy was considered optional between a LDL of 100 to <130 mg/dL. An update by the NCEP committee in 2004 based on new trial data recommended starting drug therapy simultaneously with therapeutic lifestyle changes in CHD patients with LDL < 100 mg/dL. An optional goal of LDL < 70 mg/dL was recommended in high risk patients. | NCEP ATP III guidelines recommended a LDL goal < 100 mg/dL for CHD or CHD risk equivalents, however drug therapy was considered optional between a LDL of 100 to <130 mg/dL. An update by the NCEP committee in 2004 based on new trial data recommended starting drug therapy simultaneously with therapeutic lifestyle changes in CHD patients with LDL < 100 mg/dL. An optional goal of LDL < 70 mg/dL was recommended in high risk patients. | ||
==Intensive versus moderate lowering of LDL== | ==Intensive versus moderate lowering of LDL== | ||
There is no clear consensus for intensive LDL lowering based on the available data. The data supporting intensive versus moderate LDL lowering in CHD patients will be reviewed here. In addition, recently FDA issued a black box warning about the increased risk of myopathy with high dose Simvastatin (80 mg) in patients who were never on it. This warning based on the SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial | |||
==Statins in the setting of ACS== | |||
Revision as of 17:47, 12 September 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Associate Editor(s)-In-Chief: Kashish Goel, M.D.
Overview
Patients with coronary heart disease or newly diagnosed acute coronary syndrome are at a high risk of recurrent coronary events. In addition to modification of lifestyle factors, LDL lowering has been shown to reduce recurrent events, cardiovascular deaths and all-cause mortality in these patients. According to the NCEP ATP III guidelines, LDL cholesterol of < 100 mg/dL is the goal in patients with CHD and CHD risk equivalents. The NCEP recommendations are mentioned here, in addition to recent evidence.
Therapy goals
NCEP ATP III guidelines recommended a LDL goal < 100 mg/dL for CHD or CHD risk equivalents, however drug therapy was considered optional between a LDL of 100 to <130 mg/dL. An update by the NCEP committee in 2004 based on new trial data recommended starting drug therapy simultaneously with therapeutic lifestyle changes in CHD patients with LDL < 100 mg/dL. An optional goal of LDL < 70 mg/dL was recommended in high risk patients.
Intensive versus moderate lowering of LDL
There is no clear consensus for intensive LDL lowering based on the available data. The data supporting intensive versus moderate LDL lowering in CHD patients will be reviewed here. In addition, recently FDA issued a black box warning about the increased risk of myopathy with high dose Simvastatin (80 mg) in patients who were never on it. This warning based on the SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial